Roche will publish its Full Year Results for 2022 prior to the opening of the Swiss Stock Exchange on Thursday, 2 February 2023.

 

07:00 CET / 06:00 GMT / 01:00 AM EST / 10:00 PM PST (evening before)

Release will be e-mailed and posted on the Roche IR website > click here
Presentation slides will be posted on the Roche IR website > click here

 

The webinar will start with presentations by senior management, followed by a Q&A session.



Presenters:

  • Severin Schwan, CEO Roche Group
  • Thomas Schinecker, CEO Roche Pharmaceuticals ad interim
  • Matt Sause, CEO Roche Diagnostics
  • Alan Hippe, Chief Financial and IT Officer
 

We would like to invite all interested parties to participate in the webinar and to pre-register for the event here*

 

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

 

A replay of the webcast will be available via > ir.roche.com
*privacy notice

 

Best regards,

 

 
Bruno Eschli
Head of Investor Relations

 
  


Roche Investor Relations 
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

 
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

 
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

 
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
  
Investor Relations North America 
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
 


get the latest news and updates to your inbox.